TGF-β1在子宫内膜癌组织中的表达及其与预后相关性分析
Expression of TGF-β1 in Endometrial Cancer Tissues and Its Correlation with Prognosis
DOI: 10.12677/acm.2025.1592508, PDF,    科研立项经费支持
作者: 彭亚楠*, 王 娟, 崔晨阳：石河子大学医学院，新疆 石河子；朱行行：贵州大学第一附属医院妇产科，贵州 贵阳；韩一菲：江南大学附属中心医院，江苏 无锡；李福霞, 吕锡芳#：石河子大学第一附属医院妇产科，新疆 石河子
关键词: 子宫内膜癌；TGF-β1；临床预后；Endometrial Cancer； TGF-β1； Clinical Prognosis
摘要: 目的：本研究探讨TGF-β1作为预后标志物的潜力及其与肿瘤恶性行为的相关性；方法：选取2019至2022年石河子大学医学院第一附属医院73例EC患者和30例正常子宫内膜患者作为对照。采用免疫组化检测TGF-β1蛋白表达，通过SPSS25.0软件进行统计分析。结果：研究表明，癌组织中TGF-β1表达显著高于正常内膜(P < 0.05)。TGF-β1高表达比例在IA期、高分化、肌层浸润深度 < 1/2、无淋巴结转移、肿瘤直径 < 2 cm的患者中均低于其他相应阶段(P < 0.05)。TGF-β1表达水平与3年无进展生存期(PFS)呈负相关，但与3年总生存期(OS)无显著相关性(P ≥ 0.05)；结论：TGF-β1在EC中高表达，与肿瘤恶性程度相关，可能影响无进展生存，提示其在EC发生发展中发挥重要作用。
Abstract: Objective: This study explores the potential of TGF-β1 as a prognostic marker and its correlation with tumor malignancy. Methods: From 2019 to 2022, 73 patients with endometrioid adenocarcinoma and 30 patients with normal endometrium from the First Affiliated Hospital of Shihezi University Medical College were selected. The expression of TGF-β1 protein was detected by immunohistochemistry, and statistical analysis was performed using SPSS25.0 software. Results: The study found that TGF-β1 expression in cancer tissues was significantly higher than that in normal endometrium (P < 0.05). The proportion of high TGF-β1 expression was lower in patients with stage IA, high differentiation, myometrial invasion depth < 1/2, no lymph node metastasis, and tumor diameter < 2 cm compared with other corresponding stages (P < 0.05). TGF-β1 expression level was negatively correlated with 3-year progression-free survival (PFS), but not significantly correlated with 3-year overall survival (OS) (P ≥ 0.05). Conclusion: TGF-β1 is highly expressed in endometrial cancer and is associated with tumor malignancy. It may affect progression-free survival, indicating an important role in the development of endometrial cancer.
文章引用：彭亚楠, 朱行行, 王娟, 韩一菲, 崔晨阳, 李福霞, 吕锡芳. TGF-β1在子宫内膜癌组织中的表达及其与预后相关性分析[J]. 临床医学进展, 2025, 15(9): 425-431. https://doi.org/10.12677/acm.2025.1592508

参考文献

[1] Makker, V., MacKay, H., Ray-Coquard, I., Levine, D.A., Westin, S.N., Aoki, D., et al. (2021) Endometrial cancer. Nature Reviews Disease Primers, 7, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[2] Liu, L., Habeshian, T.S., Zhang, J., Peeri, N.C., Du, M., De Vivo, I., et al. (2023) Differential Trends in Rising Endometrial Cancer Incidence by Age, Race, and Ethnicity. JNCI Cancer Spectrum, 7, pkad001. [Google Scholar] [CrossRef] [PubMed]
[3] Casadio, P., Raffone, A., Maletta, M., Travaglino, A., Raimondo, D., Raimondo, I., et al. (2021) Clinical Characteristics of Patients with Endometrial Cancer and Adenomyosis. Cancers, 13, Article 4918. [Google Scholar] [CrossRef] [PubMed]
[4] Corr, B.R., Erickson, B.K., Barber, E.L., Fisher, C.M. and Slomovitz, B. (2025) Advances in the Management of Endometrial Cancer. BMJ, 388, e080978. [Google Scholar] [CrossRef] [PubMed]
[5] Wang, C., Zhang, Z., Zhang, Y., Zheng, L., Liu, Y., Yan, A., et al. (2023) Comprehensive Characterization of TGFB1 across Hematological Malignancies. Scientific Reports, 13, Article No. 19107. [Google Scholar] [CrossRef] [PubMed]
[6] Xiong, S., Cheng, J., Klausen, C., Zhao, J. and Leung, P.C.K. (2016) TGF-β1 Stimulates Migration of Type II Endometrial Cancer Cells by Down-Regulating PTEN via Activation of SMAD and ERK1/2 Signaling Pathways. Oncotarget, 7, 61262-61272. [Google Scholar] [CrossRef] [PubMed]
[7] Ferriss, J.S., Erickson, B.K., Shih, I. and Fader, A.N. (2021) Uterine Serous Carcinoma: Key Advances and Novel Treatment Approaches. International Journal of Gynecological Cancer, 31, 1165-1174. [Google Scholar] [CrossRef] [PubMed]
[8] Sun, R., Zhao, Y., Liu, Y., Zhang, M., Qiu, Z., Ma, X., et al. (2025) Extracellular Matrix Stiffness in Endometrial Cancer: Driving Progression and Modulating Treatment Sensitivity via the ROCK1/YAP1 Axis. Cell Death & Disease, 16, Article No. 380. [Google Scholar] [CrossRef] [PubMed]
[9] Mamat Yusof, M.N., Chew, K.T., Hafizz, A.M.H.A., Abd Azman, S.H., Ab Razak, W.S., Hamizan, M.R., et al. (2023) Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis. Cancers, 15, Article 4032. [Google Scholar] [CrossRef] [PubMed]
[10] Abdul Wahab, B.I., Shah, S.A., Mohd Arshad, R., Alfian, N., Tan, G.C. and Wong, Y.P. (2025) Immunoexpressions of PD-L1 and EZH2 in Endometrial Carcinoma: Associations with Clinicopathological Parameters. Diagnostics, 15, Article 1042. [Google Scholar] [CrossRef] [PubMed]
[11] Bartoletti, M., Montico, M., Lorusso, D., Mazzeo, R., Oaknin, A., Musacchio, L., et al. (2024) Incorporation of Anti-Pd1 or Anti PD-L1 Agents to Platinum-Based Chemotherapy for the Primary Treatment of Advanced or Recurrent Endometrial Cancer. A Meta-Analysis. Cancer Treatment Reviews, 125, Article ID: 102701. [Google Scholar] [CrossRef] [PubMed]
[12] 秦廷芹. IL-23与TGF-β在子宫内膜癌患者外周血及组织中的表达及相关性研究[D]: [硕士学位论文]. 青岛: 青岛大学, 2020.

为你推荐